Deals, Partnering

CMC Biologics announces agreement with Daiichi Sankyo to develop and manufacture antibodies

Posted on 27 October 2011

Tags: , ,

Agreement with Daiichi Sankyo to provide process development support and manufacture of several clinical-stage antibodies over a three-year period. 

The two companies have recently begun work on their first joint project at CMC Biologics' Bothell manufacturing facility.

Specific terms of the agreement were not disclosed.

"CMC Biologics is delighted to partner with Daiichi Sankyo, a leader among pharmaceutical companies worldwide with a heritage of scientific discovery that spans more than one hundred years," noted Gustavo F. Mahler, Ph.D., Global Chief Operations Officer at CMC Biologics. "We will be working closely with Daiichi Sankyo on the development and production of antibodies over the next several years."

Junichi Koga, Ph.D., Vice President, Biopharmaceutical Technology Research Laboratories at Daiichi Sankyo, commented, "I believe CMC Biologics is the best partner for Daiichi Sankyo because of their depth of experience and excellent quality. Together we have created a responsive working relationship to bring best-in-class biologics to patients in need."


See the full details at Current Agreements (subscription required)

Print Friendly, PDF & Email

Leave a Reply